Study links clot-buster, angioplasty combo with increased death risk

09/7/2005 | USA Today

Many heart attack patients are given a clot-busting drug prior to a planned angioplasty, but the combined treatment could increase a patient's risk of death following the artery-widening procedure, according to a new study. Researchers studying 1,667 patients found that 6% of patients given the clot-busting drug TNKase died within 30 days of their angioplasty, compared with just 3.8% of those who had an angioplasty with no clot-buster.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC